title: NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.
abstract: NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.
authors.affiliation: Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nakada
authors.forename: Yuji
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Satoh
authors.forename: Toshiro
authors.initials: T
authors.lastname: Ono
authors.forename: Takashi
authors.initials: T
authors.lastname: Saika
authors.forename: Takushi
authors.initials: T
authors.lastname: Kurashige
authors.forename: Sacha
authors.initials: S
authors.lastname: Gnjatic
authors.forename: Gerd
authors.initials: G
authors.lastname: Ritter
authors.forename: Yao-Tseng
authors.initials: YT
authors.lastname: Chen
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Stockert
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nasu
authors.forename: Tomoyasu
authors.initials: T
authors.lastname: Tsushima
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
authors.forename: Eiichi
authors.initials: E
authors.lastname: Nakayama
mesh_terms: D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood; D000951:Antigens, Neoplasm; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D006801:Humans; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000235:genetics / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D011506:Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D014158:Transcription, Genetic
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D008565:Membrane Proteins; D011506:Proteins; D012333:RNA, Messenger